Monopar Therapeutics Inc. Additional Paid in Capital, Common Stock
Monopar Therapeutics Inc. (MNPR) had Additional Paid in Capital, Common Stock of $229.47 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-12
- 2026-06-30: Additional Paid in Capital, Common Stock $229.47M.
- 2026-03-31: Additional Paid in Capital, Common Stock $228.69M.
- 2025-12-31: Additional Paid in Capital, Common Stock $227.20M.
- 2025-09-30: Additional Paid in Capital, Common Stock $225.85M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $229.47M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $228.69M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $227.20M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $225.85M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $132.99M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $132.03M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $130.79M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $69.82M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $69.63M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $69.30M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $65.81M 10-K · filed 2025-03-31 | $65.79M 10-K · filed 2024-03-28 |
| 2023-09-30 | $64.99M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $64.25M 10-Q · filed 2023-08-10 | |
| 2022-12-31 | $61.87M 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |